Cherbourg En Cotentin

Researchers are conducting a global study to understand the impact of moderate to severe alopecia areata (AA), non-segmental vitiligo (NSV), and hidradenitis suppurativa (HS) on adolescents and adults. This study aims to assess the burden these conditions place on patients' quality of life and daily functioning in a large real-world population. The study involves participants diagnosed by a physician with one of the three conditions: AA, NSV, or HS. There are no interventional treatments or medications being tested in this study, as it is observational in nature. Data collection focuses on patient-reported outcomes and measures that evaluate disease severity and its effects. Participants will complete various questionnaires and assessments related to their condition, such as the Alopecia Areata Symptom Impact Scale (AASIS) for AA, the Severity of Alopecia Tool (SALT) for scalp hair loss in AA, the Facial Vitiligo Area Scoring Index (F-VASI) and Vitiligo Quality of Life Score (VitiQoL) for vitiligo, and the Dermatology Life Quality Index (DLQI) and International Hidradenitis Suppurativa Severity Scoring System (IHS4) for HS. These tools help researchers understand how symptoms affect quality of life and disease severity. The study collects information up to the day of the study visit.

Researchers are evaluating the effect of a triple therapy inhaler called BGF MDI containing budesonide, glycopyrronium, and formoterol fumarate compared with a dual therapy inhaler called GFF MDI containing glycopyrronium and formoterol fumarate in people with Chronic Obstructive Pulmonary Disease (COPD) who have a higher risk of heart and lung problems. This Phase III randomized, double-blind, parallel group study takes place at multiple centers and focuses on cardiopulmonary outcomes in these patients. Participants receive either the BGF MDI 320/14.4/9.6 micrograms twice daily or the GFF MDI 14.4/9.6 micrograms twice daily. The treatments are inhaled using metered dose inhalers. The study compares these two therapies over time to see how they affect the time until the first severe heart or lung event occurs. The study design ensures that neither participants nor researchers know which treatment is given to reduce bias. During the study, participants will have regular visits to the study site or virtual visits to complete assessments. Researchers will monitor lung function, symptoms, and blood tests, including blood eosinophil counts and COPD assessment test scores. The main outcome measured is the time to the first severe cardiac or COPD event, with follow-up lasting up to three years. Safety and adherence to treatment will also be closely observed throughout the study period.

Researchers are evaluating the effects of Qiseng®, a dietary supplement made from American ginseng extract combined with vitamin C from Camu Camu berries, on fatigue in female patients treated for localized breast or gynecological cancer. This multicenter randomized, placebo-controlled, double-blind trial aims to assess the safety and effectiveness of Qiseng® in reducing cancer-related fatigue experienced after treatment. Participants will be randomly assigned to receive either Qiseng® or a placebo, each given as two capsules daily for 8 weeks. The study involves a comparison between these two groups to monitor changes in fatigue levels over the treatment period. During the trial, researchers will assess participants' fatigue scores using a visual scale at one week and four weeks after finishing the 8-week treatment. Participants will be monitored for safety and adherence throughout the study, which includes follow-up assessments to measure the change in fatigue associated with the intervention.

Researchers are conducting a French prospective observational study to understand how patients aged 18 years and older with moderate to severe atopic dermatitis (AD) are managed when eligible for or currently receiving systemic therapy. The study aims to describe treatment patterns, including previous and current therapies, and monitor drug survival and compliance over time. Experienced dermatologists in hospital and office settings will participate, ensuring treatment decisions reflect real-world clinical practice. Patients will be followed for one year under routine care, with systemic treatment decisions made solely by their physicians independent of study enrollment. The study does not involve specific interventions or changes in treatment but observes the use and management of systemic therapies for AD, including topical corticosteroid use and other systemic options. Participants will complete questionnaires and undergo assessments at baseline, six months, and twelve months. Researchers will collect data on previous and current treatments, therapeutic management of atopic comorbidities, drug survival changes, and treatment adherence. The study focuses on gathering real-life information on systemic therapy use and patient outcomes over the 12-month follow-up period.

Researchers are evaluating the effectiveness of arginine-vasopressin (AVP) combined with hydrocortisone compared to norepinephrine in improving survival and neurological recovery 30 days after cardiac arrest in patients with hemodynamic failure. This phase 3 trial focuses on patients who have experienced post-resuscitation syndrome, which includes multiple organ failures and brain damage following successful resuscitation and restoration of spontaneous circulation after cardiopulmonary resuscitation. Patients are randomly assigned to receive AVP, hydrocortisone, their placebos, or a combination, in a 1:1:1:1 ratio. AVP is given by infusion to maintain a target mean arterial pressure of 65 mmHg for up to 3 days. Hydrocortisone is administered intravenously, starting with a 100 mg dose followed by 50 mg every 6 hours for 7 consecutive days, without tapering. The study involves 17 intensive care units in France and plans to enroll 380 patients. Participants will be closely monitored with evaluations including neurological outcomes measured at day 30. Researchers will assess survival and brain function recovery. The study also monitors safety and treatment adherence during the intervention period and follows patients through the critical post-resuscitation phase to capture relevant clinical outcomes.

Gout is a common inflammatory condition caused by high levels of uric acid that leads to painful joint attacks and can result in chronic joint damage, kidney problems, and increased heart risks. This study evaluates whether starting the gout treatment febuxostat immediately during an acute attack is as safe and effective as delaying treatment by six weeks, which is the current recommendation. The trial aims to compare these two approaches in patients diagnosed with gout attacks, focusing on treatment timing and its impact on the disease progression and symptoms. Participants are randomly assigned to two groups: one receives febuxostat 80 mg daily immediately for six weeks, while the other waits six weeks before starting the same treatment. After this initial six-week period, all patients receive febuxostat for an additional six weeks in an extension phase. The study also includes follow-up visits at three and six months to assess ongoing treatment effects. The febuxostat dose does not require adjustment for patients with moderate kidney function (creatinine clearance above 30 ml/min). During the study, patients track the number of days with gout symptoms daily using a booklet and report their pain and overall condition through questionnaires. Doctors perform clinical exams and monitor joint health, blood pressure, and any side effects. Laboratory tests at six and twelve weeks include uric acid, kidney and liver function, inflammation markers, and blood counts to assess treatment safety and effectiveness. The study lasts up to six months with regular assessments to monitor gout attacks and treatment tolerance.

Ventilator-associated pneumonia (VAP) is a common and serious infection in intensive care units, often leading to prolonged mechanical ventilation and excessive antibiotic use. This trial evaluates two strategies for starting antibiotic therapy in patients with suspected non-severe VAP: immediate antibiotic treatment after sampling versus waiting for microbiological confirmation before starting treatment. The study aims to balance the risks of unnecessary antibiotic exposure against the dangers of delaying therapy in infected patients, considering concerns about antibiotic resistance and patient outcomes. Participants are randomly assigned to one of two groups. The control group receives immediate empiric antibiotic therapy within one hour of randomization, based on clinical judgment and local protocols; treatment is stopped if respiratory samples are negative or continued for seven days if VAP is confirmed. The conservative strategy group waits for respiratory sample culture and/or PCR results before starting antibiotics; if results are negative, no antibiotics are given, and if positive, treatment is started promptly and continued for seven days without waiting for susceptibility testing. Throughout the study, participants are monitored for death or continued use of invasive mechanical ventilation up to 28 days. Researchers record the proportion of patients who die or remain on ventilation at 28 days as the primary outcome. The study involves patients who have been mechanically ventilated for more than 48 hours and meet specific clinical criteria for suspected VAP without signs of severe illness, with informed consent obtained from patients or their representatives.

Bronchiectasis is a chronic lung condition where parts of the bronchial tubes become permanently widened, leading to mucus buildup, infections, and ongoing inflammation. Managing this disease often includes respiratory physiotherapy to help clear mucus. However, accessing this therapy regularly can be difficult due to time, location, and availability of trained professionals. Researchers are evaluating the long-term use of the SIMEOX device, which uses brief air pressure pulses to help loosen and move mucus, combined with remote physiotherapy, to improve the quality of life and reduce lung flare-ups in adults with non-cystic fibrosis bronchiectasis. The study compares two groups: one using the SIMEOX device daily at home along with remote physiotherapy sessions, and a control group receiving enhanced standard care plus remote physiotherapy. The remote physiotherapy is delivered monthly for the first three months and then every three months afterward. The study lasts on average 24 months, allowing assessment of the device's effects over the mid and long term. Participants will be monitored through quality of life questionnaires and tracking of pulmonary exacerbations during the study. Evaluations include respiratory assessments and ensuring participants can use the device and follow procedures. The main outcomes measured are changes in respiratory quality of life after six months and the annual rate of lung exacerbations over the full study period. Safety and treatment adherence will also be continuously reviewed throughout participation.

Researchers are studying patients who have metastatic lung cancer and have survived for more than three years after their diagnosis without receiving cytotoxic chemotherapy. The focus is on understanding their clinical features, health status, quality of life, and socio-economic impacts, including the effects of cancer treatments, the occurrence of new diseases, and return to work. This observational study aims to better identify the needs of these long-term survivors to improve their management. Participants will complete several questionnaires, including the Hospital Anxiety and Depression Scale (HAD), the Quality of Life Questionnaire - Lung Cancer 13 (QLQ-LC13), and the Aix-Marseille-University (AMU) questionnaire. These are designed to assess anxiety, depression, lung cancer symptoms, treatment side effects, and overall quality of life. Questionnaires are completed at the start of the study, at 6 and 12 months, and then yearly for up to 5 years. Participants will be followed during their regular medical consultations as per usual care at participating centers. Throughout the study, researchers will collect information on clinical characteristics, treatment details, health status, socio-demographic factors, and quality of life measures. Data will be gathered at baseline and during follow-up visits up to 5 years. This information will help assess the long-term impact of lung cancer and its treatments on patients who are living well beyond initial expectations.

Researchers are gathering real-world data on patients aged 70 years and older who are receiving first-line treatment for thoracic tumors, specifically Non-Small-Cell Lung Carcinoma (NSCLC). This Phase 4 study aims to characterize patients in terms of their geriatric, biological, and cancer-related features. It will also describe treatment methods by disease stage and evaluate outcomes related to treatment effectiveness, safety, and quality of life. Subgroups of patients treated with the same medication or innovative strategies will also be explored. Participants will receive systemic treatments that are authorized and available through standard care or compassionate use. Blood samples will be collected before starting treatment and stored in a biobank for up to 10 years. Quality of life will be assessed using specific questionnaires at various time points depending on disease stage and treatment type. Geriatric assessments including autonomy scales, cognitive tests, depression screening, fall history, and social environment evaluations will be performed. During the study, participants will follow their usual clinical care with regular visits, laboratory tests, imaging, and biopsies as needed to monitor their general health, treatment effectiveness, and side effects. They will complete quality of life questionnaires and undergo assessments tailored for older adults. Researchers will measure progression-free survival, defined as the time from first treatment dose until disease progression or death, with follow-up lasting up to two years.